(Q30322732)

18 June 2017

1 reference

title

Drug-resistant Streptococcus pneumoniae: rational antibiotic choices. (English)

1 reference

18 June 2017

main subject

antibiotic resistance

0 references

Streptococcus pneumoniae

1 reference

Jacobs MR

1

1 reference

18 June 2017

language of work or name

English

0 references

publication date

1 May 1999

1 reference

American Journal of Medicine

18 June 2017

published in

1 reference

18 June 2017

volume

106

1 reference

18 June 2017

issue

5A

1 reference

18 June 2017

page(s)

19S-25S; discussion 48S-52S

1 reference

Antimicrobial-drug resistance

18 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP). A strategy from the DRSP Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Emerging resistance to antimicrobial agents in gram-positive bacteria. Pneumococci.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Epidemiology and prevention of pneumococcal infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Trends in antimicrobial drug prescribing among office-based physicians in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Parental Issues in Selection of Antimicrobial Agents for Infants and Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

The clinical impact of resistance in the management of pneumococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Activity of penicillin and three third-generation cephalosporins against US isolates of Streptococcus pneumoniae: a 1995 surveillance study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Emerging antibiotic resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Antibiotic resistance in Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Management of infections caused by antibiotic-resistant Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Multiply resistant pneumococcus causing meningitis: its epidemiology within a day-care centre

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Pneumococcal meningitis during therapy of otitis media with clarithromycin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Meningitis due to ceftriaxone-resistant Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Rationale behind high-dose amoxicillin therapy for acute otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Defining resistance: breakpoints and beyond implications for pediatric respiratory infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Antibiotic management of pneumococcal infections in an era of increased resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Choice of an oral beta-lactam antibiotic for infections due to penicillin-resistant Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Pharmacodynamic effects of amoxicillin versus cefotaxime against penicillin-susceptible and penicillin-resistant pneumococcal strains: a phase I study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

30 years of penicillin-resistant S pneumoniae: myth or reality?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900351-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(98)00351-9

1 reference

18 June 2017

1 reference